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assays from different laboratories (8). Data from this study indicated that values from different laboratories can be compared only with reservations. In particular, the chromatographic purification involved in these assays seemed to be a critical step.
The positive reactions to this first collaborative study prompted an international extension of the project. At the moment this kind of comparative study is the only way for a laboratory to compare its values with those obtained by several other investigators in the field. To our knowledge, there are as yet no reference sera or solutions available for use in vitamin D metabolite assays.
In this study we compared the results for the three major 
1,25(OH)2D.
Because the participants were asked to perform three assays on each sample, and because of the costly and laborious procedures required, the number of samples was limited to eight. This implies that we could obtain only a rough indication of intra-assay variation and no data on the interassay variation of each participant. However, the major aim of this study was to assess the current status of interlaboratory comparability of the rapidly increasing amount of data on vitamin D metabolite concentrations. This paper discusses the results of 25(OH)D assays from 19 laboratories, 24,25(OH)2D assays from 12 laboratories, and 1,25(OH)2D assays from 15 laboratories.
Materials and Methods

Standard Solutions
Crystalline
25(OH)D3 was obtained from Duphar
By, Weesp, The Netherlands.
Crystalline 24,25(OH)2D3 and 1,25(OH)2D3 were a gift from Hoffmann-LaRoche, Basle, Switzerland.
Solutions of 25(OH)D3 were prepared by weighing an amount of 25(OH)D3 on a Cahn Model 4100
analytical balance and dissolving the metabolite in ethanol. The other two metabolites came in preweighed amounts and were also dissolved in ethanol. Concentrations of the solutions were calculated based on these weights. Molar absorptivities at 263 nra, calculated from these data, were 18 600, 18 500, and 17 900 for 25(OH)D3, 24,25(OH)2D3, and Before shipment of the samples all solutions were checked for purity by normal (straight)-phase HPLC as described before (10) and by ultraviolet spectroscopy.
Plasma Samples
A thoroughly stirred pooled specimen of plasma from healthy blood donors was divided into eight portions. Three of these portions were divided into 5-mL aliquots, with no further modification. Another portion was diluted to 0.6 times its original concentration with isotonic saline containing 5.3 g of fatty-acid-free human serum albumin per liter.
This albumin solution contained no detectable quantities of the metabolites under investigation. To another portion we added, per liter, 25 nmol of 25(OH)D3, 2.4 nmol of 24,25(OH)2D3, and 48 pmol of 1,25(OH)2D3. To the three remaining portions we added only one metabolite, but in the same quantity as was added to the portion that was fortified with all three metabolites.
The concentrations of the samples were prepared so as to match those of the standards. After the additions the plasma samples were thoroughly stirred and divided into 5-mL aliquots. Table 1 summarizes the modifications of the plasma pools. All samples were stored at -20 #{176}C until shipment on solid CO2. The participants did not know the sequence of the plasma samples, nor did they know the concentrations of the samples and the standard solutions.
Assay Procedures
All participants performed the measurements according to their own procedures.
They were asked to assay all samples in a single run, in order to confine assay variation to intra-assay variation only. In general, vitamin D metabolite assays consist of three steps: the serum or plasma sample is extracted with an organic solvent, the extract is purified by one or more chromatographic steps, and in a final step it is quantified, usually by competitive protein binding or radioimmunoassay procedures. All these steps may differ for each laboratory, and in addition they may also differ for each metabolite, resulting in a large number of different procedures. It is therefore not possible to discuss the assay procedures in detail. However, Table 2 gives a concise general description of the methods.
Statistical Methods
All statistical calculations were performed with a Cyber 170-750 computer with use of the "Statistical Package for the Social Sciences" (11). Ninety-percent confidence intervals were calculated based on the standard deviation of the five unmodified samples for each metabolite.
We calculated Pearson's product moment correlation coefficient between the results for the standard solutions and plasma samples, using the average result of each laboratory for the five unmodified samples and the averaged z-score of each laboratory for the two standard solutions of that particular metabolite. The z-score of a participant for a standard solution was the number of standard deviations by which the result deviated from the interlaboratorSr mean for that solution. The z-scores of the two standard solutions for each metabolite were averaged for each participant.
The average was used to calculate the correlation.
Results
At the start of this study, requests for participation were sent to 34 laboratories. Of these, 27 agreed to participate and subsequently received the samples as described. Eventually, 18 laboratories sent us the results of their measurements. All participants confirmed that the samples were still frozen on arrival. Including the Amsterdam laboratory, measurements from 19 laboratories could thus be compared. Table 3 lists the names of the participants. Table 4 gives the interlaboratory mean and standard deviation of the results for the plasma samples and the standard solutions for each metabolite. To obtain at least an indication of the intra-assay coefficient of variation for each laboratory, we included five plasma samples with the same concentration for a particular metabolite (see Table 1 ). for the diluted and fortified samples are shown in Table 6 . As can be seen in Tables 6 and 4 , interlaboratory averages of the results for the standard solutions as well as for the fortified and unfortified plasma samples were very close to the calculated values. The CVs, however, were rather large. The only value which deviates substantially from its calculated value is the result for the plasma samples with added 24,25(OH)2D. To verify the influence of the concentrations of the standard solutions of each laboratory on their results for the plasma samples, we calculated the correlation between the values for the plasma samples and those for the standard solutions that were sent to the participants. As is shown in Table 7 , there was very little correlation between results for the standards and the plasma samples.
Discussion
In a previous survey on vitamin D metabolite assays in the Netherlands (8) we found low interlaboratory CVs for the measurement of standard solutions. Substantially higher variation was found for plasma or serum samples. This indicated that much of the variation was ascribable to the wide variety of purification procedures used by the participants. Surprisingly, we found a lower interlaboratory CV for binding assay (12-14) .
The amount of these compounds in the final quantification can depend on the extraction procedure, the prepurification, and the number of washes of the HPLC column. From the data Table 3 . List of Participants a available it was not possible to give an explanation for the extremely high values found by the two laboratories. Country   In contrast to the findings for the 1,25(OH)2D assay, the Only 53% of the laboratories were able to discriminate these three samples from the unmodified samples with their 1,25(OH2D assays.This means that a significant proportion of the participants, especiallyfor the 1,25(OH)2D assay, cannot reliablydetect important physiologicalchanges in the circulating concentrations of vitamin D metabolites. It should be kept in mind, however, that this conclusion is based on a small number of measurements in one assay and should therefore only be interpreted as a general indication of the current precision of vitamin D metabolite determinations.
U.S.A. variation for the 25(OH)D and 24,25(OH)2D assays seemed
Because of the increased interlaboratory variation for the standard solutions as compared with the previous study, we looked for any relationship between this variation and the variation of the plasma samples. Calculating the correlation between the results for the standard solutions and the results for the plasma samples for each metabolite, we found very low correlations in the case of the 25(OH)D and 24,25(OH)2D assays, no correlation in the case of the 1,25(OH)2D assay. This means that the interlaboratory variation in results for the plasma samples is independent of the values found for the standard solutions. The fact that there is considerable interlaboratory variation for the standards, in the absence of any significant correlation between results for standards and plasma samples, indicates that at least two factors contributed to the interlaboratory variation in resultsforthe plasma samples. This was confirmed by the fact that the CVs for the samples were higher than for the assays. However, the fortified and diluted samples differed considerably in concentration from the unchanged samples. Thus, intra-assay variation could be responsible for the observed interlaboratory variation for the standard solutions, but it is not so large as to prevent the participants from distinguishing the modified and unmodified samples. The second possibility does not seem to be very important. Large differences between the standards of the participants would probably result in a correlation between the results for the plasma samples and those for the standards. This indicates that the differences in purification procedures probably are responsible for much of the interlaboratory variation, with an important contribution from intralaboratory variation in the final quantificaNo. of labs. tion method.
17
From the results presented here it is clear that for an 11 extensive clinicaluse of the described assays each labora-13 tory should firmly establish its own reference intervals.
Comparison of values with those from another laboratory is not reliable without an actual comparison of the procedures. Because interassay variation is usually even larger than intra-assay variation, each laboratory that performs these assays should apply strict quality controls-for example, by using reference sera in each assay. This is especially important in long-term clinical studies or studies requiring a large number of assays.
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